Small cell lung carcinoma

Researchers are testing whether giving adebrelimab, apatinib mesylate, and chemotherapy before surgery helps people with limited-stage small cell lung cancer. The study enrolls adults with early-stage disease that surgeons can remove. Participants receive the drug combination for…

This early-phase trial is testing an experimental therapy called DLL3-SAVVYZ-IL18 CAR T cells in people with advanced neuroendocrine cancers, including small cell lung cancer. The treatment involves reprogramming a patient's own immune cells to recognize and attack cancer cells t…

This phase 1 trial tests a new type of CAR-T cell therapy designed to target a protein called DLL3 found on small cell lung cancer cells. The CAR-T cells are also modified to boost their activity through PD-L1 and 4-1BB signals. The study enrolls adults with relapsed or refractor…

This study tests a new drug combination (alisertib plus paclitaxel) in people with small cell lung cancer who have already tried other treatments. The main goal is to find safe doses and see what side effects occur. About 50 adults will take alisertib pills and receive paclitaxel…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

This Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…

This phase 3 trial is testing whether tarlatamab, an immunotherapy drug, can be given as a quick injection under the skin instead of a slow intravenous drip for people with relapsed extensive-stage small cell lung cancer. The study will compare the two methods to see if the injec…

This Phase 2 trial tests whether combining lurbinectedin (Zepzelca) with durvalumab (Imfinzi) as maintenance therapy can delay cancer growth in people with extensive-stage small-cell lung cancer whose disease has not worsened after initial chemotherapy plus durvalumab. About 50 p…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take par…

Researchers at Emory University are testing intensity-modulated proton therapy (IMPT) for people with small cell lung cancer. Proton therapy delivers radiation to tumors while reducing exposure to nearby healthy organs like the heart. The study enrolls 30 adults with limited or e…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This early-phase trial is testing a new oral drug called iadademstat combined with radiation therapy and the immunotherapy atezolizumab in people with extensive-stage small-cell lung cancer that has persisted, returned, or worsened after first-line treatment. The study will enrol…

This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

Researchers are testing whether adding tislelizumab and anlotinib after chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without their cancer coming back. The study enrolls adults aged 18 to 75 whose cancer has not worsened after concurrent …

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This study tests a new gene therapy (quaratusugene ozeplasmid) plus an immunotherapy drug (atezolizumab) as maintenance treatment for people with extensive stage small cell lung cancer. The goal is to see if the combination can keep the cancer from growing longer than standard ca…

This phase 2 trial tests a combination of tarlatamab (a targeted immune therapy), chemotherapy, and atezolizumab in 50 adults whose lung cancer has transformed from a common type (adenocarcinoma) to a more aggressive small cell form after initial treatment. The goal is to see if …

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This trial tests whether tarlatamab, a drug that helps the immune system attack cancer cells, can improve survival in people with advanced small-cell lung cancer whose general health is poor. The study includes 57 participants who have already had at least one prior treatment. Re…

This study tests whether a team of specialists—including surgeons, oncologists, and geriatricians—can create better treatment plans for elderly lung cancer patients. 2,000 people aged 60-90 will receive personalized care based on their overall health and cancer type. The goal is …

This study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…

This study tests a new medicine called Risvutatug rezetecan (Ris-Rez) that targets a specific protein (B7-H3) on cancer cells to stop their growth. It is for adults with relapsed small cell lung cancer who have already tried one prior treatment. About 420 participants will be ran…

This study tests a new drug called ivonescimab, given with standard chemotherapy, for people with extensive-stage small cell lung cancer who haven't had treatment yet. Ivonescimab is a special antibody that helps the immune system fight cancer and may also block blood vessels tha…

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in people with extensive-stage small cell lung cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 100 adults aged 18 to 75 with good performan…

This study tests a new drug called ECI830, alone or with other cancer drugs (ribociclib and fulvestrant), in people with advanced hormone receptor-positive, HER2-negative breast cancer or certain solid tumors. The goal is to find safe doses and see if the combination can slow can…

This early-stage trial tests a new drug called BL-B01D1 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find a safe dose, and second, to check how well that dose works and how the body handles it. About 570 p…

This study is testing two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. BNT324 targets and delivers a toxin to cancer cells, while BNT327 helps the immune system attack tumors and cuts off their blood supply. The…

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This early-stage trial is testing whether giving durvalumab as a shot under the skin works as well as the standard IV infusion. About 40 adults with various solid tumours will receive the injection, and researchers will measure drug levels in the blood and watch for side effects.…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study tests a new drug (BL-M14D1) combined with an approved immunotherapy (atezolizumab) in 36 adults with extensive-stage small cell lung cancer that has no standard treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants mus…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This trial is testing whether a new experimental drug called YL201, when combined with the immunotherapy serplulimab, can help people with extensive-stage small cell lung cancer live longer compared to the current standard treatment (carboplatin and etoposide plus serplulimab). T…

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take …

This study tests a new drug called ZL-1310, alone or with standard treatments (atezolizumab and carboplatin), in people with small cell lung cancer. About 339 participants will join to see if the combination is safe and shrinks tumors. The goal is to find better ways to control t…

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…

This early-phase trial is testing a new drug called ST-001 in people with small cell lung cancer that has returned or not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 44 participants will receive the drug through an …

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This Phase 2 trial tests the drug alisertib in 120 people with extensive stage small cell lung cancer that has worsened after standard treatments like chemotherapy and immunotherapy. The goal is to see if alisertib can shrink tumors or slow the disease, and to identify which pati…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…

This study is exploring whether giving radiotherapy at the same time as immunotherapy and chemotherapy, versus giving it after, works better as a first treatment for extensive-stage small cell lung cancer. The trial will enroll about 60 adults with this advanced cancer. Participa…

This study tests personalized radiotherapy approaches for people with lung cancer, brain metastases, or other solid tumors. It aims to see if adapting radiation based on how a patient responds is safe and effective. About 45 adults will participate, receiving either extra radiati…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…

This study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…

This phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if…

This study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…

This phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…

This trial is testing whether adding radiation to the chest can help people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread widely. Participants first receive standard chemotherapy plus an immunotherapy drug, and if their cancer does not worsen,…

This trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with in…

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This early-phase study tests whether combining valemetostat with atezolizumab is safe as maintenance therapy for people with extensive-stage small cell lung cancer. Researchers will try different doses of valemetostat to find the best one with few side effects. The study involves…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive either I-DXd or a treatment chosen by their doctor. The g…

This trial is testing a new type of cell therapy for adults with small cell lung cancer that has returned or not responded to standard treatments. The therapy uses immune cells called natural killer (NK) cells, engineered to recognize and attack cancer cells through two targets a…

This trial is testing whether a pill form of the chemotherapy drug paclitaxel, taken alongside an immune checkpoint inhibitor, can help people with advanced lung cancer stay stable longer after their first round of treatment. The study includes two groups: one with squamous non-s…

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen…

This study tests a drug called tarlatamab in 35 adults with small cell lung cancer that has spread to the brain but is not causing symptoms. The goal is to see if the drug can shrink or control these brain tumors. Participants must have already had standard chemotherapy and be in…

This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…

This phase 3 trial is testing whether adding one or two immune-boosting antibodies—toripalimab alone or combined with tifcemalimab—after standard chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without the cancer growing. About 756 particip…

This study tests a new combination of drugs (BL-B01D1 and tislelizumab) against standard chemotherapy plus tislelizumab as the first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. About 562 adults with good performance status will join th…

This early-stage trial is testing a new oral drug called NMS-03305293, combined with the chemotherapy temozolomide, in 10 people with relapsed small cell lung cancer. The main goal is to check safety and tolerability, while also looking for signs that the tumors shrink. All parti…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 monoclonal antibody can shrink tumors in people with extensive-stage small cell lung cancer. The study enrolls 66 adults aged 18 to 75 who have newly diagnosed, advanced disease. Res…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This study tests whether a drug called adebrelimab can help keep limited-stage small cell lung cancer from coming back after initial chemotherapy and radiation. About 200 adults aged 18-75 with untreated, limited-stage disease will be randomly assigned to receive either standard …

This phase 2 trial tests a combination of two drugs—HLX43 and serplulimab—in 120 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combo can shrink tumors and control the disease. Participants must have cancer that has spread or come back …

This study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…

This study tests a new drug called IDE849, alone or with other drugs, in people with cancers that have a protein called DLL3, including small cell lung cancer. The trial has two phases and aims to see if the drug is safe and shrinks tumors. About 208 participants who have already…

This study tests a drug called tarlatamab as a maintenance treatment for people with limited-stage small cell lung cancer who cannot receive standard combined chemotherapy and radiation. After completing chemotherapy with or without radiation, participants who have not gotten wor…

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch…

This early-phase study tests a new drug called HLX3901 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 138 adults aged 18 to 75 will take part.

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This Phase 2 trial tests tarlatamab, a bispecific antibody that helps immune cells attack cancer cells, in 39 patients with extensive-stage small-cell lung cancer. The goal is to see if it can delay cancer growth and improve survival. Participants will receive tarlatamab and unde…

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. The approach combines the drug bemotuzumab with standard chemotherapy and another drug called anlotinib, followed by chest radiation. The goal is to see if t…

This early-phase trial is testing a drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has worsened after standard chemotherapy. The main goals are to check safety and side effects, and to see how the drug behaves i…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. About 65 adults who had their cancer completely removed will receive the combination for 12 weeks, then durva…

This early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to ta…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests if trilaciclib can protect bone marrow in people with limited-stage small cell lung cancer receiving chemotherapy. About 120 participants will get either trilaciclib or a placebo. The goal is to reduce severe low white blood cell counts and other complications fr…

This early-phase trial is testing whether combining two drugs, lurbinectedin and osimertinib, is safe and effective for a rare type of lung cancer called transformed small cell lung cancer. The study will enroll 16 adults whose cancer has changed from a common form to this more a…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This phase 2 trial is testing whether adding the drug QL1706 to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. QL1706 is a type of immunotherapy that targets two immune checkpoints to help the body fight cancer. The study will enrol…

This early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests whether stereotactic radiosurgery (SRS), a precise form of radiation, can effectively treat brain metastases in people newly diagnosed with small cell lung cancer that has spread to the brain. About 62 participants will receive SRS, and researchers will track how…

This phase 2 trial is testing whether a combination of two drugs, lurbinectedin and serplulimab, can help keep extensive-stage small cell lung cancer from growing when used as maintenance therapy after initial chemo-immunotherapy. About 30 adults whose cancer has not worsened aft…

This early-stage trial is testing a new drug called IBI115, alone or with other treatments, in 150 people with advanced small cell lung cancer. The main goals are to check safety, find the right dose, and look for early signs that the drug might help control the disease.

This phase 2 trial tests whether adding chest radiotherapy to maintenance immunotherapy (atezolizumab) can better control extensive-stage small cell lung cancer. About 37 adults whose cancer shrank after initial chemo-immunotherapy will receive targeted radiation to the chest alo…

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This trial tests whether adding the drug niraparib to standard maintenance therapy can help people with a specific type of advanced small cell lung cancer (SLFN11-positive) stay cancer-free longer. About 44 participants will receive niraparib pills plus an anti-PD-L1 antibody aft…

This early-phase trial is testing whether combining two drugs, tarlatamab and AB248, is safe and tolerable for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. About 380 adults will take part. The main goals are to check for…

This study tests whether lower doses of chemotherapy can effectively control lung cancer in patients aged 70+ or those with other health problems. About 280 participants will receive pre-set reduced chemo doses to see if tumors shrink while causing fewer side effects. The goal is…

This study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …

This study tests a combination of four drugs (JS212, JS207, Toripalimab, and JS213) in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will receive the drugs by …

This early-phase study tests an experimental therapy called V001 Injection, which aims to create cancer-fighting cells directly inside the body. It is for people with advanced blood cancers or solid tumors that have not responded to standard treatments. The main goals are to chec…

This study compares two drug combinations for people with extensive-stage small-cell lung cancer who haven't had prior treatment. One group gets teniposide, cisplatin, and serplulimab; the other gets the standard etoposide, cisplatin, and serplulimab. The goal is to see which com…

This Phase 2 trial tests an oral drug called veonetinib (AL8326) in 80 adults with advanced small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma who have already tried at least one prior treatment. The study aims to find the best dose and see if the drug ca…

This study tests a new drug called SKB518 in 192 adults with lung cancer (non-small cell or small cell). The goal is to see if it shrinks tumors and to check for side effects. Participants receive the drug alone until their disease gets worse or side effects become too severe.

This study tests a new drug combination (SKB500) in 80 adults with small cell lung cancer, a fast-growing type of lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow the disease. Participants must be 18-75 and have extensive-stage cancer, with s…

This study tests a new treatment for people with a specific type of advanced small cell lung cancer (SLFN-11 positive). The treatment combines low-dose radiation, chemotherapy, an immunotherapy drug (sugemalimab), and a targeted drug (olaparib). The goal is to see if this combina…

This early-phase study tests a new treatment called GC511B for adults with small cell lung cancer that has come back or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cel…

This study tests a combination of two drugs, monalizumab and durvalumab, plus chemotherapy for people with small cell lung cancer. The goal is to see if this mix can keep the cancer from growing longer than standard treatment. About 84 adults with either extensive or limited stag…

This study tests a new drug called ZG006 combined with standard immunotherapy (with or without chemotherapy) as a first treatment for people with extensive-stage small cell lung cancer. About 100 adults aged 18-75 with good performance status are being recruited. The main goals a…

This study tests a new treatment for people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread. The treatment combines the drug tislelizumab with chemotherapy and radiation to the chest. The goal is to see if this combination can help control the c…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This phase II trial tests whether combining the chemotherapy drug temozolomide with the immunotherapy atezolizumab can shrink tumors or prolong survival in people with advanced small cell lung cancer that has spread or returned. About 56 participants who have already had one or t…

This phase 1 trial tests a personalized, accelerated radiation therapy for locally advanced lung cancer. The radiation dose is tailored to each patient's tumor size and location, aiming to deliver a higher dose in fewer sessions. The study will enroll 45 adults with non-small cel…

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…

This Phase 3 trial tests whether giving higher doses of radiation twice a day can improve outcomes for people with limited-stage small cell lung cancer. All 300 participants will receive standard chemotherapy and be randomly assigned to one of three radiation dose levels. The stu…

This Phase 2 trial tests whether adding trilaciclib to the chemotherapy drug lurbinectedin can reduce severe neutropenia (a dangerous drop in white blood cells) in people with small cell lung cancer that has spread. About 30 participants will receive both drugs intravenously. The…

This study tests whether using biomarker tests to personalize maintenance therapy can help control extensive-stage small cell lung cancer. About 900 participants will receive durvalumab alone or combined with other drugs based on their cancer subtype. The goal is to see if this t…

This phase 2 trial tests fingolimod, a drug already used for multiple sclerosis, in 38 adults with advanced non-small cell or small cell lung cancer that worsened after chemo-immunotherapy. Participants take a 0.5 mg pill daily. The study first checks safety, then looks at whethe…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This phase II trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with limited-stage small-cell lung cancer live longer without their cancer returning. About 100 participants will receive durvalumab plus chemo b…

This study tests a new treatment called CAR-NK cells, which are immune cells engineered to recognize and attack cancer. The trial enrolls 60 adults with small cell lung cancer that has come back or not responded to standard treatments. Participants receive the cells along with ch…

This study tests a new combination of two oral drugs, Stenoparib and Temozolomide, in people whose small cell lung cancer has returned after initial treatment. The trial uses a blood test (biomarker) to see who might benefit most from the combo, comparing it to the standard drug …

This study tests a new drug called SNB-101, a nanoparticle version of a chemotherapy agent, in people with extensive stage small cell lung cancer that has progressed after standard treatment. The trial has two phases: phase 1 checks safety and the best dose, while phase 2 looks a…

This Phase 3 trial is testing whether AK112 (Ivonescimab), a bispecific antibody that targets both PD-1 and VEGF, can help prevent cancer progression in people with limited-stage small-cell lung cancer who have completed chemoradiation. About 560 participants will receive either …

This early-stage study tests the safety of combining the drug talazoparib with low-dose chest radiation in people with extensive-stage small cell lung cancer that has not worsened after initial chemotherapy. About 24 participants will receive talazoparib pills daily during radiat…

This study is for people newly diagnosed with extensive-stage small cell lung cancer that has spread. Researchers want to see if adding a precise, high-dose radiation treatment (ablative radiation) to the standard combination of durvalumab (an immunotherapy) and chemotherapy (car…

This early-stage study tests a new drug called FZ-AD005 in people with advanced solid tumors, especially small cell lung cancer and large cell neuroendocrine carcinoma. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 162 partic…

This study tests whether adding the targeted drug anlotinib to whole-brain radiation helps control brain tumors better than radiation alone in people with small cell lung cancer. About 134 participants with up to 10 brain metastases will be enrolled. The goal is to see if the com…

This phase II trial tests whether adding two drugs—toripalimab (an immunotherapy) and surufatinib (a targeted therapy)—to standard chemoradiation can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 47 adults aged 18–75 wi…

This phase 2 trial tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help people with extensive-stage small cell lung cancer (SCLC) stay progression-free longer. Twenty adults who have not yet been treated for their advanced SCLC will receive t…

This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in everyday medical practice. Researchers will track 500 patients to see side effects, survival time, and how long the cancer stays under control. The goal i…

This study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. Participants first get a drug called tislelizumab plus chemotherapy, then chest radiation if the cancer shrinks, followed by maintenance tislelizumab fo…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study …

This early-phase study tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy (tislelizumab) as maintenance therapy for people with extensive-stage small cell lung cancer that has a specific marker (SSTR). The goal is to see if this combination is saf…

This study tests whether adding probiotics (good bacteria) to standard chemoradiation and immunotherapy can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 60 adults aged 18-80 will take part. The goal is to see if this c…

This study tests whether adding a low dose of radiation to a combination of chemotherapy and an immunotherapy drug (adebrelimab) helps people with extensive-stage small cell lung cancer live longer. About 202 adults aged 18-75 who have not had prior treatment for this stage will …

This early-phase study tests a new drug called ALPS12 in people with extensive-stage small cell lung cancer that has returned after prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 122 participants will ta…

This study tests whether combining two drugs, niraparib and dostarlimab, can control advanced cancers that have spread to the brain. It includes 120 adults with certain cancer types like BRCA-mutated or lung cancers. The goal is to see if the treatment shrinks or stabilizes brain…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) combined with standard immunotherapy (atezolizumab) and sometimes chemotherapy (carboplatin) for people with extensive-stage small cell lung cancer who have not yet been treated. The goal is to see if the combinatio…

This early-phase study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells. The main goal is to fi…

This study tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 36 participants will receive the combination for 4 cy…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This program provides early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous…

This early-phase trial tests whether adding acetazolamide (a drug used for altitude sickness) to standard chemoradiation or radioimmunotherapy can help treat small cell lung cancer. About 27 adults with either localized or extensive small cell lung cancer will receive the combina…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…

This study tests two experimental drugs, ZG006 and ZG005, given together by IV in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial aims to see if the combination is safe and can shrink tumors. About 350 adults aged 18 to 70 are being recruited at…

This study tests an experimental drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or cannot tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 w…

This Phase 3 trial compares a new drug called ZG006 with standard chemotherapy in 420 people whose small cell lung cancer has returned. The main goal is to see if ZG006 helps patients live longer. Participants will receive either ZG006 or one of several chemo options chosen by th…

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This study looks at the safety and effectiveness of the immunotherapy drug durvalumab in 25 people with limited-stage small cell lung cancer who have already had chemotherapy and radiation. The drug is given as a follow-up treatment to try to keep the cancer from coming back. Res…

This study tests whether combining the immunotherapy drug adebrelimab with the chemotherapy drug etoposide (as capsules) can help control extensive-stage small cell lung cancer after initial treatment. About 32 adults in China will receive the combination every three weeks until …

This study tests whether adding lamivudine, an antiviral drug, to standard chemotherapy and immunotherapy can prevent or delay drug resistance in people with extensive-stage small cell lung cancer. About 28 adults will receive the combination treatment. The goal is to see if this…

This phase 2 trial is testing a drug called onvansertib in about 37 people with small cell lung cancer that has come back or hasn't responded to chemotherapy. Onvansertib works by blocking a protein that cancer cells need to grow and repair themselves. The main goal is to see if …

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …

This study tests a personalized vaccine called LK101, made from a patient's own tumor markers, combined with standard immunotherapy drugs (pembrolizumab, durvalumab, or tislelizumab) in 60 adults with advanced lung cancer. The goal is to see if the combination is safe and can hel…

This study tests a drug called teniposide in people with a fast-growing type of lung cancer (extensive-stage small cell lung cancer) that has a specific gene change (c-Myc-driven). The cancer must have gotten worse after standard treatments. The goal is to see if teniposide can s…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This study tests a new treatment for advanced small cell lung cancer that has stopped responding to standard therapies. The treatment combines an oncolytic virus (Olvi-Vec) with standard chemotherapy drugs. The goal is to see if this combination is safe and can shrink tumors in 2…

This early-stage trial is testing a new treatment called TC-D101 CAR-T for people with a specific type of advanced small cell lung cancer that has stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to target cancer cells, and is giv…

This study tests whether adding extra immunotherapy drugs to standard chemotherapy can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, all receiving the immunotherapy ivones…

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This study tests a new biologic drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it shrinks tumors (Phase 2). About 265 participants will receive ZG00…

This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with extensive-stage small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for up to a year. The goal is to see if it delays canc…

This study tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer getting worse. About 56 adults who have not had prior treatment for this advanced can…

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enr…

This early-phase study tests a new drug called BL-M14D1 in 22 adults with advanced small cell lung cancer, neuroendocrine tumors, or other solid cancers that have not responded to standard treatments. The drug is given by IV every 3 weeks. The main goals are to check safety, find…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study tests whether adding trilaciclib before standard chemotherapy (topotecan) can help people with extensive-stage small cell lung cancer live longer. About 302 participants will receive either trilaciclib or a placebo before their chemo, and researchers will compare overa…

This study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…

This study tests a new type of PET/CT scan that looks for a protein called DLL3 on small cell lung cancer cells. The goal is to see if this scan can find tumors more clearly than standard imaging methods like CT or regular PET scans. About 20 adults with suspected or confirmed sm…

This study is testing a new radioactive probe called PFD3, used with a PET/CT scan, to see if it can better find and assess small cell lung cancer (SCLC) by targeting a protein called DLL3 found on cancer cells. About 30 adults with SCLC will receive both a standard FDG scan and …

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study is looking for biomarkers—clues in the body—that could help find lung cancer early. Over 3,600 participants, including people at high and low risk for lung cancer, will provide samples and undergo CT scans. The goal is to see if these biomarkers can spot tumors before …

This study is testing whether measuring telomeres (parts of your DNA) in a blood sample can help doctors diagnose lung cancer. Researchers will collect blood from 1,200 people, including those with lung cancer and healthy volunteers, to build a predictive algorithm. The goal is t…

This early-stage study is testing a new imaging agent called 68Ga-FL-031 to see if it can better detect and stage certain cancers, including small cell lung, breast, and nasopharyngeal tumors. Ten adults with suspected or confirmed cancer will receive both the new PET scan and a …

This study is testing whether a very powerful 7 Tesla MRI can detect tiny brain metastases earlier than standard 1.5 or 3 Tesla MRIs in people with small-cell lung cancer who choose not to have preventive brain radiation. Twenty participants will get a 7T brain scan followed by u…

This study tests whether a special PET/MRI scan using a radioactive tracer called Ga68-DOTATATE can better detect certain brain tumors (like meningioma) and tell them apart from changes caused by past treatments. About 200 adults with these tumors will get the scan alongside stan…

Researchers are studying whether nutritional support helps people with advanced lung cancer maintain their weight, strength, and quality of life during chemotherapy. The trial enrolls 100 adults with high nutritional risk. Participants receive dietary advice or a structured nutri…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study tests whether a mobile app called THRIVE can help people with newly diagnosed advanced lung cancer feel better day-to-day. Researchers will compare quality of life, physical and emotional symptoms, and coping skills between app users and those receiving usual care. The…

This study tests a Hospital-at-Home program for people with small cell lung cancer receiving tarlatamab. The goal is to see if monitoring patients at home using telemedicine is as safe and effective as keeping them in the hospital after treatment. About 70 adults will take part, …

This study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…

This study tests a brief program called Pathways, designed to help people with advanced lung cancer set personal goals and improve their mental health and quality of life during treatment. About 234 participants will be randomly assigned to receive either the Pathways program or …

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This phase 3 trial tests whether a daily nutritional drink (Oral Impact®) can reduce severe throat and esophagus inflammation caused by chest radiation in lung cancer patients. About 121 adults with lung cancer who need radiation will drink two bottles a day during and for three …

This study tests whether regular phone support from a trained lay health worker can improve quality of life for veterans with lung cancer. 194 veterans will either receive usual care or weekly calls for 6 months. The goal is to see if this extra support helps with healthcare plan…

This study tests whether a special imaging method (4DCT) can help doctors avoid giving too much radiation to healthy, working parts of the lung during radiotherapy for lung cancer. About 100 adults with lung cancer will receive standard radiation, but their treatment plan will be…

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

This early-phase study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…

This study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…

This study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemothera…

This study is testing whether regular heart and lung monitoring, along with blood samples, can predict side effects in people with lung cancer receiving radiation and immunotherapy. The goal is to find early warning signs of heart or lung damage before symptoms appear. The trial …

This study aims to create a rapid autopsy program for people with small cell lung cancer (SCLC). Within 10 hours of death, researchers collect tumor and blood samples to study the disease's biology. The goal is to generate new cell lines and genetic data that could lead to better…

This study follows 600 people with lung cancer or mesothelioma to track how their tumors evolve during and after treatment. Researchers collect blood, tissue, and imaging samples every few months to understand why some cancers come back or stop responding to therapy. The goal is …

This study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …

This study is observing 200 people with extensive stage small cell lung cancer to learn more about the genetic makeup of their tumors. Researchers will analyze tumor tissue and blood samples to see if certain genetic patterns are linked to how well treatments work. The goal is to…

This pilot study explores whether eating high-fermented foods (like yogurt and kimchi) followed by high-fiber supplements can change the gut microbiome and improve immune response in people with melanoma or lung cancer who are receiving standard immunotherapy. Researchers will tr…

This study is testing whether a 12-week home-based walking program can change the immune system in people with lung cancer. Fifty patients will either do moderate continuous walking, high-intensity interval walking, or receive standard exercise advice. Researchers will measure ch…

This study is gathering detailed information from 500 people with small cell lung cancer to learn how to tailor treatments like radiation and immunotherapy to each patient. The goal is to find the best timing and doses of radiotherapy to work with immunotherapy, improving outcome…

This study looks at people with advanced lung cancer who have lived at least three years after diagnosis and are no longer on chemotherapy. Researchers want to understand their health, quality of life, and social or financial challenges. Participants will fill out questionnaires …

This study is creating a large database of 10,000 lung cancer patients who received radiation therapy. Researchers will collect information on tumor control, side effects, and quality of life to build models that predict outcomes. The goal is to use these models to select the bes…

This study looks at how lung cancer and its treatment affect patients' physical fitness. About 90 adults with lung cancer will take a special exercise test before and after starting treatment to measure how well their heart, lungs, and muscles work during exercise. The goal is to…

This pilot study will test whether lung cancer patients can use an Apple Watch, a home pulse oximeter, and a smartphone to collect health data during proton beam radiotherapy. About 40 participants will wear the devices from the start of treatment until two weeks after it ends. T…

This study is watching how lung cancer patients do when they get the drug tislelizumab in normal doctor visits, not in a strict research setting. About 240 people with small cell or non-small cell lung cancer will take part. The goal is to see how long they live, how the drug aff…

This study is collecting blood and tumor samples from 730 newly diagnosed lung cancer patients at Nantes University Hospital. Researchers will follow patients from diagnosis until death to understand how treatments work in real life, especially for patients often left out of clin…

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study looks at whether a technology that analyzes immune system T cells can predict how well a combination of the drug tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. Researchers will enroll 40 patients who have not yet be…

This study is building a large database of blood samples, tumor samples, and scans from 4,000 people with lung cancer. Researchers will follow participants for up to 10 years to collect information that can help future studies. The goal is to better understand lung cancer and imp…

This study aims to learn more about lung cancer in adults diagnosed at age 45 or younger. Researchers will collect blood samples and medical information from 500 participants to study the biology of these cancers and look for genetic changes that could lead to better treatments. …

This research study collects sputum and tissue samples from 700 people with precancerous changes or certain cancers (lung, head and neck, esophageal). The goal is to find biomarkers—biological signs—that could help understand or detect these cancers earlier. Participants include …

This observational study is collecting blood samples and medical images from 200 people with several types of solid tumors (like lung, head and neck, and esophageal cancers) who are receiving immunotherapy and radiation as part of their standard care. Researchers want to see if c…

This study is a registry that will collect information from about 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will track patients' health, treatments, and outcomes during routine care. The goal is to better understand lung cancer in Algeria and help …

This study is tracking 300 people with advanced small cell lung cancer who are taking the drug Zepzelca (lurbinectedin) after their first chemotherapy stopped working. Researchers want to see how well the drug shrinks tumors and what side effects occur in everyday hospital settin…

This study collects tumor samples from 50 lung cancer patients whose disease has worsened while on immunotherapy. The goal is to analyze the tissue for clues about why the treatment stopped working. No new drug is being tested; instead, researchers hope to better understand resis…